Literature DB >> 15919622

Immune reconstitution disease associated with mycobacterial infections in HIV-infected individuals receiving antiretrovirals.

Stephen D Lawn1, Linda-Gail Bekker, Robert F Miller.   

Abstract

Immune reconstitution disease (IRD) in HIV-infected patients is an adverse consequence of the restoration of pathogen-specific immune responses during the initial months of highly active antiretroviral treatment (HAART). Previously subclinical infections are "unmasked" or pre-existing opportunistic infections clinically deteriorate as host immunopathological inflammatory responses are "switched on". IRD is most frequently associated with mycobacterial infections. Our literature search identified 166 published cases of IRD associated with mycobacterial infections. We review the underlying immunological mechanisms, difficulties surrounding case definition and diagnosis, the wide diversity of clinical manifestations, and treatment. The importance of screening patients for mycobacterial disease before starting HAART and the critical impact of the timing of commencement of HAART in patients receiving treatment for tuberculosis are highlighted. We also discuss the problem of IRD associated with mycobacterial diseases in developing countries where tuberculosis prevalence is high and access to HAART is currently expanding.

Entities:  

Mesh:

Year:  2005        PMID: 15919622     DOI: 10.1016/S1473-3099(05)70140-7

Source DB:  PubMed          Journal:  Lancet Infect Dis        ISSN: 1473-3099            Impact factor:   25.071


  151 in total

1.  [Immune reconstitution syndrome].

Authors:  D Meyer-Olson; D Ernst; M Stoll
Journal:  Z Rheumatol       Date:  2012-04       Impact factor: 1.372

Review 2.  Nontuberculous mycobacteria and the lung: from suspicion to treatment.

Authors:  Emmet E McGrath; Zoe Blades; Josie McCabe; Hannah Jarry; Paul B Anderson
Journal:  Lung       Date:  2010-04-09       Impact factor: 2.584

Review 3.  Tuberculosis and HIV Coinfection.

Authors:  Judith Bruchfeld; Margarida Correia-Neves; Gunilla Källenius
Journal:  Cold Spring Harb Perspect Med       Date:  2015-02-26       Impact factor: 6.915

Review 4.  Immune reconstitution inflammatory syndrome in patients starting antiretroviral therapy for HIV infection: a systematic review and meta-analysis.

Authors:  Monika Müller; Simon Wandel; Robert Colebunders; Suzanna Attia; Hansjakob Furrer; Matthias Egger
Journal:  Lancet Infect Dis       Date:  2010-04       Impact factor: 25.071

5.  Progressive symptoms and signs following institution of highly active antiretroviral therapy and subsequent antituberculosis therapy: immune reconstitution syndrome or infection?

Authors:  R F Miller; M Shahmanesh; M D Talbot; M J Wiselka; P J Shaw; C Bacon; C M Robertson
Journal:  Sex Transm Infect       Date:  2006-04       Impact factor: 3.519

6.  Leprosy after starting antiretroviral treatment.

Authors:  Stephen D Lawn; Diana N J Lockwood
Journal:  BMJ       Date:  2007-02-03

7.  Antiretroviral therapy and the control of HIV-associated tuberculosis. Will ART do it?

Authors:  S D Lawn; A D Harries; B G Williams; R E Chaisson; E Losina; K M De Cock; R Wood
Journal:  Int J Tuberc Lung Dis       Date:  2011-05       Impact factor: 2.373

Review 8.  HIV and tuberculosis coinfection: inextricably linked liaison.

Authors:  Vincent Idemyor
Journal:  J Natl Med Assoc       Date:  2007-12       Impact factor: 1.798

9.  Tuberculosis after initiation of antiretroviral therapy in low-income and high-income countries.

Authors:  Martin W G Brinkhof; Matthias Egger; Andrew Boulle; Margaret May; Mina Hosseinipour; Eduardo Sprinz; Paula Braitstein; François Dabis; Peter Reiss; David R Bangsberg; Martin Rickenbach; Jose M Miro; Landon Myer; Amanda Mocroft; Denis Nash; Olivia Keiser; Margaret Pascoe; Stefaan van der Borght; Mauro Schechter
Journal:  Clin Infect Dis       Date:  2007-10-22       Impact factor: 9.079

10.  Anti-retroviral therapy reduces incident tuberculosis in HIV-infected children.

Authors:  Andrew Edmonds; Jean Lusiama; Sonia Napravnik; Faustin Kitetele; Annelies Van Rie; Frieda Behets
Journal:  Int J Epidemiol       Date:  2009-05-15       Impact factor: 7.196

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.